Payment overview · 2025
General Payments
$36,383.81
70 reported records · 16 companies
Healthcare provider profile · identity verified
Sekhar Dharmarajan, MD
Allopathic & Osteopathic Physicians|Surgery · SAINT LOUIS, MO · NPI 1093928483
Verified facts
What the public records show
CMS Open Payments records show Sekhar Dharmarajan, MD received $36,383.81 in general payments during 2025 across 70 reported records.
INTUITIVE SURGICAL, INC. accounted for 97.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
Braintree Laboratories, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUTAB as an associated drug or biological on 3132 records involving 2335 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sutab by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $35,514.11 | 97.6% | 43 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $233.20 | 0.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $96.61 | 0.3% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $78.29 | 0.2% | 3 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $74.98 | 0.2% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $63.03 | 0.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$54.46 | 0.1% | 1 | 2025 |
| TELA Bio, Inc. | Unresolved — no canonical attribution shown | $46.96 | 0.1% | 2 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $37.07 | 0.1% | 2 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $36.47 | 0.1% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $34.73 | 0.1% | 2 | 2025 |
| Elucent Medical | Unresolved — no canonical attribution shown | $25.30 | 0.1% | 1 | 2025 |
| Braintree Laboratories, Inc. | Unresolved — no canonical attribution shown | $25.20 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.81 | 0.1% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $21.10 | 0.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.49 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $30,000.00 | 10 |
| Food and Beverage | $2,711.85 | 48 |
| Travel and Lodging | $2,171.96 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500.00 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $35,514.11 | 43 | 2025 |
Source payment records
|
|||||
| Phasix Mesh Normalized: phasix mesh |
Device | Davol Inc. | $233.20 | 3 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $96.61 | 4 | 2025 |
Source payment records
|
|||||
| INTERSTIM Normalized: interstim |
Device | Medtronic, Inc. | $54.46 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) Normalized: ovitex reinforced bioscaffold with permanent polymer ovitex |
Device | TELA Bio, Inc. | $46.96 | 2 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| PREVENA Normalized: prevena |
Device | Solventum Corporation | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| DEFLUX METAL NEEDLE Normalized: deflux metal needle |
Device | Teleflex LLC | $36.47 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| SUFLAVE Normalized: suflave |
Drug | Braintree Laboratories, Inc. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.INSTILL Normalized: v a c instill |
Device | Solventum Corporation | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| CoolSeal Generator Normalized: coolseal generator |
Device | Hologic Sales and Service, LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C. VERAFLO Normalized: v a c veraflo |
Device | Solventum Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| V.A.C.ULTA Normalized: v a c ulta |
Device | Solventum Corporation | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Braintree Laboratories, Inc. Exact reporting entity; no affiliate inference |
2025 | SUTAB open payments reported associated product |
CMS Open Payments — General Payments 3132 supporting records · 2335 recipient NPIs · example record 1173775820 |
Sutab · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metronidazole | Metronidazole | 65 | 59 |
| Neomycin Sulfate | Neomycin Sulfate | 53 | 52 |
| Sodium Chloride | 0.9 % Sodium Chloride | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 37 |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 22 |
| Peg 3350-Electrolyte | Sodium Chloride/Nahco3/Kcl/Peg | 13 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,383.81 · 70 records | INTUITIVE SURGICAL, INC. | ACTIV.A.C., AQUACEL AG+ EXTRA, CoolSeal Generator, DEFLUX METAL NEEDLE, Da Vinci Surgical System, GATTEX, ICLUSIG, IMFINZI, INTERSTIM, Integra, Integra Dermal Regeneration Template, JOURNAVX, KEYTRUDA, KEYTRUDA QLEX, OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex), PREVENA, PRIMATRIX, Phasix Mesh, SUFLAVE, V.A.C. VERAFLO, V.A.C.INSTILL, V.A.C.ULTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Braintree Laboratories, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error